• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Biogen Inc.

    5/6/25 5:26:23 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BIIB alert in real time by email
    FWP 1 d905655dfwp.htm FWP FWP

    Filed pursuant to Rule 433

    Registration No.: 333-286915

    Free Writing Prospectus dated May 6, 2025

    Relating to Preliminary Prospectus Supplement dated May 6, 2025

    (to Prospectus dated May 1, 2025)

    $1,750,000,000

    Biogen Inc.

    $400,000,000 5.050% Senior Notes Due 2031

    $650,000,000 5.750% Senior Notes Due 2035

    $700,000,000 6.450% Senior Notes Due 2055

    PRICING TERM SHEET

    $400,000,000 5.050% Senior Notes Due 2031

     

    Issuer    Biogen Inc.
    Principal Amount    $400,000,000
    Maturity Date    January 15, 2031
    Interest Payment Dates    Semi-annually, each January 15 and July 15, commencing January 15, 2026
    Benchmark Treasury    3.875% due April 30, 2030
    Benchmark Treasury Price; Yield    99-28 1⁄4 / 3.901%
    Spread to Benchmark Treasury    115 basis points
    Yield to Maturity    5.051%
    Interest Rate    5.050% per annum beginning on the Issue Date
    Issue Price (Price to Public)    99.981%
    Optional Redemption   

    Make-whole call, in whole or in part, as set forth in the preliminary prospectus supplement (Treasury Rate (as defined in the preliminary prospectus supplement) plus 20 basis points) at any time prior to December 15, 2030 (one month prior to the maturity date of the notes due 2031)

     

    Par call, in whole or in part, at any time on or after December 15, 2030 (one month prior to the maturity date of the notes due 2031)

    CUSIP/ISIN    09062XAN3/US09062XAN30


    $650,000,000 5.750% Senior Notes Due 2035

     

    Issuer    Biogen Inc.
    Principal Amount    $650,000,000
    Maturity Date    May 15, 2035
    Interest Payment Dates    Semi-annually, each May 15 and November 15, commencing November 15, 2025
    Benchmark Treasury    4.625% due February 15, 2035
    Benchmark Treasury Price; Yield    102-15+ / 4.310%
    Spread to Benchmark Treasury    145 basis points
    Yield to Maturity    5.760%
    Interest Rate    5.750% per annum beginning on the Issue Date
    Issue Price (Price to Public)    99.924%
    Optional Redemption   

    Make-whole call, in whole or in part, as set forth in the preliminary prospectus supplement (Treasury Rate (as defined in the preliminary prospectus supplement) plus 25 basis points) at any time prior to February 15, 2035 (three months prior to the maturity date of the notes due 2035)

     

    Par call, in whole or in part, at any time on or after February 15, 2035 (three months prior to the maturity date of the notes due 2035)

    CUSIP/ISIN    09062XAL7/US09062XAL73


    $700,000,000 6.450% Senior Notes Due 2055

     

    Issuer    Biogen Inc.
    Principal Amount    $700,000,000
    Maturity Date    May 15, 2055
    Interest Payment Dates    Semi-annually, each May 15 and November 15, commencing November 15, 2025
    Benchmark Treasury    4.500% due November 15, 2054
    Benchmark Treasury Price; Yield    94-28+ / 4.826%
    Spread to Benchmark Treasury    165 basis points
    Yield to Maturity    6.476%
    Interest Rate    6.450% per annum beginning on the Issue Date
    Issue Price (Price to Public)    99.657%
    Optional Redemption   

    Make-whole call, in whole or in part, as set forth in the preliminary prospectus supplement (Treasury Rate (as defined in the preliminary prospectus supplement) plus 25 basis points) at any time prior to November 15, 2054 (six months prior to the maturity date of the notes due 2055)

     

    Par call, in whole or in part, at any time on or after November 15, 2054 (six months prior to the maturity date of the notes due 2055)

    CUSIP/ISIN    09062XAM5/US09062XAM56


    Terms Applicable to All Tranches

     

    Expected Ratings*    Baa2 (stable) / BBB+ (stable) (Moody’s/S&P)
    Trade Date    May 6, 2025
    Settlement Date**    May 12, 2025
    Change of Control    Upon the occurrence of a Change of Control Triggering Event (as defined in the preliminary prospectus supplement to which this pricing term sheet relates) with respect to a series of notes, Biogen Inc. will be required to make an offer to purchase the notes of such series at a price equal to 101% of their principal amount plus accrued and unpaid interest to but not including the date of repurchase.
    Joint Book-Running Managers   

    BofA Securities, Inc.

    Citigroup Global Markets Inc.

    J.P. Morgan Securities LLC

    Deutsche Bank Securities Inc.

    Mizuho Securities USA LLC

    Morgan Stanley & Co. LLC

    U.S. Bancorp Investments, Inc.

    Wells Fargo Securities, LLC

    Co-Managers   

    BBVA Securities Inc.

    Scotia Capital (USA) Inc.

    TD Securities (USA) LLC

    Academy Securities, Inc.

    Blaylock Van, LLC

    Loop Capital Markets LLC

     

    *

    None of the securities ratings is a recommendation to buy, sell or hold the notes. Each rating may be subject to revision or withdrawal at any time, and should be evaluated independently of any other rating.

    **

    Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes prior to the date that is one business day preceding the settlement date will be required, by virtue of the fact that the notes initially will settle T+4, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of notes who wish to trade the notes prior to the date that is one business day preceding the settlement date should consult their own advisors.

    The issuer has filed a registration statement (including a prospectus) and a preliminary prospectus supplement with the Securities and Exchange Commission (“SEC”) for the offerings to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement and other documents the issuer has filed with the SEC for more complete information about the issuer and these offerings. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offerings will arrange to send you the prospectus if you request it by calling BofA Securities, Inc. toll free at 1 (800) 294-1322; Citigroup Global Markets Inc. toll free at 1 (800) 831-9146; or J.P. Morgan Securities LLC collect at 1 (212) 834-4533.

    ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED (OTHER THAN ANY STATEMENT RELATING TO THE IDENTITY OF THE LEGAL ENTITY AUTHORIZING OR SENDING THIS COMMUNICATION IN A NON-US JURISDICTION). SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION HAVING BEEN SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.

    Get the next $BIIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIIB

    DatePrice TargetRatingAnalyst
    12/10/2025$143.00Hold → Reduce
    HSBC Securities
    11/6/2025$202.00Hold → Buy
    Stifel
    9/25/2025$190.00Buy
    Jefferies
    7/21/2025$142.00Hold
    Truist
    4/28/2025$118.00Buy → Hold
    HSBC Securities
    4/4/2025Buy → Hold
    Argus
    2/11/2025$160.00Mkt Perform
    Bernstein
    1/2/2025$315.00 → $138.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $BIIB
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.

    SCHEDULE 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/13/25 8:28:22 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Biogen Inc.

    SCHEDULE 13G - BIOGEN INC. (0000875045) (Subject)

    11/10/25 8:15:23 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Biogen Inc.

    10-Q - BIOGEN INC. (0000875045) (Filer)

    10/30/25 6:31:48 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-15) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211855, Application Classification: Labeling

    3/25/24 4:41:37 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biogen downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Biogen from Hold to Reduce and set a new price target of $143.00

    12/10/25 8:14:55 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen upgraded by Stifel with a new price target

    Stifel upgraded Biogen from Hold to Buy and set a new price target of $202.00

    11/6/25 8:40:16 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies initiated coverage on Biogen with a new price target

    Jefferies initiated coverage of Biogen with a rating of Buy and set a new price target of $190.00

    9/25/25 8:28:11 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Viehbacher Christopher converted options into 7,040 shares and covered exercise/tax liability with 3,404 shares, increasing direct ownership by 28% to 16,443 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    12/3/25 4:42:56 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Head of Research Grogan Jane converted options into 695 shares and covered exercise/tax liability with 337 shares, increasing direct ownership by 25% to 1,791 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    11/4/25 4:12:56 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Accounting Officer Godbout Sean converted options into 26 shares and covered exercise/tax liability with 8 shares, increasing direct ownership by 4% to 495 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    10/6/25 1:00:24 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Annual Changes to the Nasdaq-100 Index®

    NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on Monday, December 22, 2025. The following six companies will be added to the Index: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Ferrovial SE (NASDAQ:FER), Insmed Incorporated (NASDAQ:INSM), Monolithic Power Systems, Inc. (NASDAQ:MPWR), Seagate Technology Holdings plc (NASDAQ:STX), Western Digital Corp. (NASDAQ:WDC). The Nasdaq-100 Index is a globally recognized index that tracks the performance of 100 of the largest non-financial companies listed on the Nasdaq Stock Market® encompassi

    12/12/25 8:00:00 PM ET
    $ALNY
    $BIIB
    $CDW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Retail: Computer Software & Peripheral Equipment

    "LEQEMBI®" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

    TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")) announced today that anti-Aβ protofibril* antibody "LEQEMBI®" (brand name in China: "乐意保®", generic name: lecanemab), has been included in the "Commercial Insurance Innovative Drug List" (Chinese: 商业健康保险创新药品目录), recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of LEQEMBI in this list marks a meaningful step toward expanding access to early Alzheimer's Disease (AD) treatment in China. The Com

    12/8/25 6:30:00 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

    —Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life— —Propensity score weighted analysis comparing the effects of zorevunersen to natural history showed reductions in seizures and improvements in cognition and behavior with dose levels and timepoints similar to and consistent with the ongoing Phase 3 EMPEROR study— —Analysis of electroencephalogram (EEG) supports a disease-modifying mechanism of action— Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology

    12/5/25 9:00:00 AM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BIIB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dorsa Caroline bought $151,559 worth of shares (1,235 units at $122.72), increasing direct ownership by 5% to 27,842 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    5/5/25 4:17:10 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rowinsky Eric K bought $101,256 worth of shares (455 units at $222.54), increasing direct ownership by 2% to 20,629 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    2/20/24 9:13:26 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Leadership Updates

    Live Leadership Updates

    View All

    /C O R R E C T I O N -- National Association of Corporate Directors/

    In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows: Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- Th

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

    Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- The National Association of Corporate Directors® (NACD®) today announced the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker, Global Assurance Leader at PwC, to its board of directors, effective immediately. The appointments bring to NACD a wealth of experience spanning technology, innovation, assurance, governance and capital markets — further strengthening the association's ability to guide directors as they navigate today's rapidly evolving business landscape. Mant

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

    BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

    6/3/25 7:00:00 AM ET
    $BIIB
    $TRDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BIIB
    Financials

    Live finance-specific insights

    View All

    Annual Changes to the Nasdaq-100 Index®

    NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on Monday, December 22, 2025. The following six companies will be added to the Index: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Ferrovial SE (NASDAQ:FER), Insmed Incorporated (NASDAQ:INSM), Monolithic Power Systems, Inc. (NASDAQ:MPWR), Seagate Technology Holdings plc (NASDAQ:STX), Western Digital Corp. (NASDAQ:WDC). The Nasdaq-100 Index is a globally recognized index that tracks the performance of 100 of the largest non-financial companies listed on the Nasdaq Stock Market® encompassi

    12/12/25 8:00:00 PM ET
    $ALNY
    $BIIB
    $CDW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Retail: Computer Software & Peripheral Equipment

    Biogen Completes Acquisition of Alcyone Therapeutics

    CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system. ThecaFlex DRx™ is an investigational implantable device designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines, which could ease both patient experience and accessibility for a broader population of people living with neurologic disorders. ThecaFlex DRx™ has been in development since 2019, with the PIERRE and PIERRE-PK clinical studies for nusinersen curren

    11/14/25 4:05:00 PM ET
    $BIIB
    $IONS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

    Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and quality of lifePresentation of preclinical study of DZP showing minimal to no human placental transfer CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced upcoming presentations from studies evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate, in systemic lupus erythematosus (SLE) to be presented at the American College of Rheumatology (ACR) Convergence 2025 (October 24-29) in Chicago, Illinois. The presentations will show effi

    10/22/25 7:30:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/12/24 1:24:28 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/4/24 11:20:12 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Biogen Inc.

    SC 13G - BIOGEN INC. (0000875045) (Subject)

    10/16/24 12:11:53 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care